Curigliano, Giuseppe http://orcid.org/0000-0003-1781-2518
Dent, Rebecca
Llombart-Cussac, Antonio
Pegram, Mark http://orcid.org/0000-0002-9743-8118
Pusztai, Lajos http://orcid.org/0000-0001-9632-6686
Turner, Nicholas http://orcid.org/0000-0001-8937-0873
Viale, Giuseppe
Funding for this research was provided by:
Pfizer
Article History
Received: 5 January 2022
Accepted: 6 June 2023
First Online: 28 June 2023
Competing interests
: G.C. declares no Competing Non-Financial Interests but the following Competing Financial Interests: The author has received institutional financial support and served as an advisor for clinical trials from Bristol-Myers Squibb, Roche, Novartis, Eli Lilly, Pfizer, Daiichi Sankyo, Celcuity, Veracyte, Seagen, AstraZeneca, and Ellipses Pharma. R.D. declares no Competing Non-Financial Interests but the following Competing Financial Interests: The author has served as an advisory consultant for AstraZeneca, Eisai, Merck Sharp & Dohme, Novartis, Pfizer, and Roche; has received fees for expenses from Eisai, Merck Sharp & Dohme, Pfizer, and Roche. A.L-C. declares no Competing Non-Financial Interests but the following Competing Financial Interests: The author has patents and intellectual property with MEDSIR and owns stock in MEDSIR; has served in a leadership role for Eisai, Celgene-BMS, Eli Lilly, Pfizer, Roche, Novartis, Merck Sharp & Dohme, and TESARO-GSK; has been a consultant/advisory board member for Eli Lilly, Roche, Pfizer, Novartis, Pierre Fabre, Genomic Health, and TESARO-GSK; has received speakers bureau honoraria from Eli Lilly, AstraZeneca, Merck Sharp & Dohme, Pfizer, and Roche; has received institutional research funding from Roche, Foundation Medicine, Pierre Fabre, and Agendia; has received fees for expenses, travel, and accommodations (paid or reimbursed) by Roche, Eli Lilly, Novartis, Pfizer, and AstraZeneca. M.P. declares no Competing Non-Financial Interests but the following Competing Financial Interests: The author has received consultation fees from Roche/Genentech, Pfizer, Seagen, and Eli Lilly. L.P. declares no Competing Non-Financial Interests but the following Competing Financial Interests: The author has received consultation fees and honoraria from Seagen, Pfizer, AstraZeneca, Merck, Novartis, Bristol-Myers Squibb, Genentech, Eisai, Pieris Pharmaceuticals, Immunomedics, Clovis Oncology, Syndax, H3 Biomedicine, Radius Health, Personalis, Daiichi Sankyo, Natera; has received institutional research funding from Seagen, AstraZeneca, Merck, Pfizer, and Bristol-Myers Squibb. N.T. declares no Competing Non-Financial Interests but the following Competing Financial Interests: The author has received advisory board honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech, GlaxoSmithKline, Zentalis Pharmaceuticals, Repare Therapeutics, Arvinas; has received research funding from AstraZeneca, BioRad, Pfizer, Roche/Genentech, Merck Sharp & Dohme, Guardant Health, Invitae, Inivata, Personalis, and Natera. G.V. declares no Competing Non-Financial Interests but the following Competing Financial Interests: The author has received consultation fees from Dako/Agilent, Roche, MSD Oncology, AstraZeneca, Daiichi Sankyo, Pfizer, and Eli Lilly.